Juniper Pharmaceuticals (JNP) versus Amicus Therapeutics (FOLD) Head to Head Analysis

Juniper Pharmaceuticals (NASDAQ: JNP) and Amicus Therapeutics (NASDAQ:FOLD) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Insider & Institutional Ownership

36.4% of Juniper Pharmaceuticals shares are owned by institutional investors. 7.2% of Juniper Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Juniper Pharmaceuticals and Amicus Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Juniper Pharmaceuticals $54.57 million 1.25 $5.95 million $0.60 10.50
Amicus Therapeutics $4.96 million 505.18 -$200.04 million ($1.83) -8.23

Juniper Pharmaceuticals has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Juniper Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Juniper Pharmaceuticals and Amicus Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 1 2 0 2.67
Amicus Therapeutics 0 1 6 0 2.86

Juniper Pharmaceuticals presently has a consensus target price of $23.00, indicating a potential upside of 265.08%. Amicus Therapeutics has a consensus target price of $18.64, indicating a potential upside of 23.71%. Given Juniper Pharmaceuticals’ higher possible upside, research analysts plainly believe Juniper Pharmaceuticals is more favorable than Amicus Therapeutics.

Profitability

This table compares Juniper Pharmaceuticals and Amicus Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals 10.80% 17.32% 11.65%
Amicus Therapeutics -1,092.37% -63.54% -23.46%

Risk & Volatility

Juniper Pharmaceuticals has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500.

Summary

Juniper Pharmaceuticals beats Amicus Therapeutics on 10 of the 14 factors compared between the two stocks.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

About Amicus Therapeutics

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply